$RARE
Ultragenyx Pharmaceutical Inc. Stock $rare

$rare Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024017879 Filed on February 21, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$108.8M	$127.4M	$434.2M
YoY Change	8.3%	23.27%	19.52%
Cost Of Revenue	$17.53M	$12.05M	$45.21M
YoY Change	43.04%	126.57%	59.64%
Gross Profit	$91.30M	$115.3M	$389.0M
YoY Change	3.47%	17.66%	16.13%
Gross Profit Margin	83.89%	90.54%	89.59%
Selling, General & Admin	$78.16M	$76.83M	$309.8M
YoY Change	1.98%	5.47%	11.38%
% of Gross Profit	85.61%	66.61%	79.63%
Research & Development	$178.5M	$160.6M	$648.4M
YoY Change	7.72%	-6.0%	-8.12%
% of Gross Profit	195.5%	139.2%	166.68%
Depreciation & Amortization	$8.845M	$8.216M	$26.01M
YoY Change	68.93%	65.75%	42.73%
% of Gross Profit	9.69%	7.12%	6.68%
Operating Expenses	$256.6M	$237.4M	$958.2M
YoY Change	5.9%	-2.57%	-2.61%
Operating Profit	-$165.3M	-$122.0M	-$569.2M
YoY Change	7.3%	-16.19%	-12.28%
Interest Expense	$12.57M	$1.889M	$397.0K
YoY Change	111.05%	-76.5%	-104.83%
% of Operating Profit
Other Income/Expense, Net	-$1.605M	-$6.732M	-$39.65M
YoY Change	-621.1%	-57.1%	2432.12%
Pretax Income	-$170.2M	-$126.9M	-$608.5M
YoY Change	4.13%	-17.22%	-13.29%
Income Tax	$455.0K	-$3.702M	-$1.825M
% Of Pretax Income
Net Earnings	-$170.7M	-$123.2M	-$606.6M
YoY Change	4.09%	-18.86%	-14.25%
Net Earnings / Revenue	-156.83%	-96.7%	-139.7%
Basic Earnings Per Share	-$2.03		-$8.25
Diluted Earnings Per Share	-$2.03	-$1.52	-$8.25
COMMON SHARES
Basic Shares Outstanding	82.34M	82.11M	73.54M
Diluted Shares Outstanding	84.29M		73.54M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$412.1M	$577.2M	$577.2M
YoY Change	-34.52%	-22.81%	-22.81%
Cash & Equivalents	$112.3M	$213.6M	$213.6M
Short-Term Investments	$299.8M	$363.6M	$363.6M
Other Short-Term Assets	$47.73M	$47.62M	$47.62M
YoY Change	-29.16%	-30.92%	-30.92%
Inventory	$35.91M	$33.97M	$33.97M
Prepaid Expenses
Receivables	$100.3M	$73.39M	$73.39M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$596.0M	$732.2M	$732.2M
YoY Change	-22.23%	-17.16%	-17.16%
LONG-TERM ASSETS
Property, Plant & Equipment	$285.1M	$290.6M	$314.5M
YoY Change	2.6%	11.87%	10.07%
Goodwill	$44.41M	$44.41M
YoY Change	0.0%	0.0%
Intangibles	$165.0M	$166.3M
YoY Change	3.69%	3.85%
Long-Term Investments	$156.6M	$199.9M	$199.9M
YoY Change	73.19%	29.38%	29.38%
Other Assets	$59.97M	$57.69M	$33.79M
YoY Change	169.42%	242.43%	100.55%
Total Long-Term Assets	$711.1M	$758.8M	$758.8M
YoY Change	15.24%	14.71%	14.71%
TOTAL ASSETS
Total Short-Term Assets	$596.0M	$732.2M	$732.2M
Total Long-Term Assets	$711.1M	$758.8M	$758.8M
Total Assets	$1.307B	$1.491B	$1.491B
YoY Change	-5.52%	-3.52%	-3.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$40.97M	$42.11M	$42.11M
YoY Change	-30.53%	-2.68%	-2.68%
Accrued Expenses	$149.1M	$196.5M	$209.1M
YoY Change	3.27%	-4.0%	-3.33%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$245.6M	$280.4M	$280.4M
YoY Change	12.56%	7.36%	7.36%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$14.48M	$12.21M	$905.1M
YoY Change	56.41%	153.22%	0.56%
Total Long-Term Liabilities	$14.48M	$12.21M	$905.1M
YoY Change	56.41%	153.22%	0.56%
TOTAL LIABILITIES
Total Short-Term Liabilities	$245.6M	$280.4M	$280.4M
Total Long-Term Liabilities	$14.48M	$12.21M	$905.1M
Total Liabilities	$1.167B	$1.216B	$1.216B
YoY Change	0.33%	1.9%	1.9%
SHAREHOLDERS EQUITY
Retained Earnings	-$3.558B	-$3.388B
YoY Change	20.83%	21.81%
Common Stock	$83.00K	$82.00K
YoY Change	16.9%	17.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$3.332M	$432.0K
YoY Change	835.96%
Treasury Stock Shares
Shareholders Equity	$140.3M	$275.4M	$275.4M
YoY Change
Total Liabilities & Shareholders Equity	$1.307B	$1.491B	$1.491B
YoY Change	-5.52%	-3.52%	-3.52%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$170.7M	-$123.2M	-$606.6M
YoY Change	4.09%	-18.86%	-14.25%
Depreciation, Depletion And Amortization	$8.845M	$8.216M	$26.01M
YoY Change	68.93%	65.75%	42.73%
Cash From Operating Activities	-$190.7M	-$83.91M	-$474.8M
YoY Change	21.59%	-7.12%	24.8%
INVESTING ACTIVITIES
Capital Expenditures	$3.211M	$1.597M	$44.27M
YoY Change	-87.17%	-94.08%	-61.88%
Acquisitions			$0.00
YoY Change			-100.0%
Other Investing Activities	$2.065M	-$105.4M	$5.048M
YoY Change	-47.73%	-27.11%	498.1%
Cash From Investing Activities	$94.44M	-$107.0M	$168.0M
YoY Change	-15.16%	-37.63%	-157.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-58.00K	330.6M	388.1M
YoY Change	-91.97%	17467.06%	-22.56%
NET CHANGE
Cash From Operating Activities	-190.7M	-83.91M	-474.8M
Cash From Investing Activities	94.44M	-107.0M	168.0M
Cash From Financing Activities	-58.00K	330.6M	388.1M
Net Change In Cash	-97.03M	139.7M	81.80M
YoY Change	110.59%	-153.71%	-147.56%
FREE CASH FLOW
Cash From Operating Activities	-$190.7M	-$83.91M	-$474.8M
Capital Expenditures	$3.211M	$1.597M	$44.27M
Free Cash Flow	-$193.9M	-$85.50M	-$519.1M
YoY Change	6.62%	-27.11%	4.53%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001515673
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Current Asset Statement Of Financial Position Extensible List RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsCurrent
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Current Asset Statement Of Financial Position Extensible List RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsCurrent
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Current Asset Statement Of Financial Position Extensible List RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsCurrent
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent Asset Statement Of Financial Position Extensible List RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent Asset Statement Of Financial Position Extensible List RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent Asset Statement Of Financial Position Extensible List RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023	us-gaap	Collaborative Arrangement Transaction Statement Of Income Or Comprehensive Income Extensible Enumeration CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RevenueFromContractWithCustomerExcludingAssessedTax
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.ultragenyx.com/20231231#OperatingAndFinanceLeaseLiabilityCurrent
CY2023Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.ultragenyx.com/20231231#OperatingAndFinanceLeaseLiabilityCurrent
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.ultragenyx.com/20231231#OperatingAndFinanceLeaseLiabilityNoncurrent
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.ultragenyx.com/20231231#OperatingAndFinanceLeaseLiabilityNoncurrent
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-36276
CY2023	dei	Entity Registrant Name EntityRegistrantName	Ultragenyx Pharmaceutical Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-2546083
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	60 Leveroni Court
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Novato
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94949
CY2023	dei	City Area Code CityAreaCode	415
CY2023	dei	Local Phone Number LocalPhoneNumber	483-8800
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2023	dei	Trading Symbol TradingSymbol	RARE
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	3100000000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	82335687
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	San Mateo, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	213584000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	132944000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	363625000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	614818000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	73390000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	40445000
CY2023Q4	us-gaap	Inventory Net InventoryNet	33969000
CY2022Q4	us-gaap	Inventory Net InventoryNet	26766000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	47616000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	68926000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	732184000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	883899000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	290566000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	259726000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	199901000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	148970000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	166271000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	160105000
CY2023Q4	us-gaap	Goodwill Goodwill	44406000
CY2022Q4	us-gaap	Goodwill Goodwill	44406000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	57685000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	48338000
CY2023Q4	us-gaap	Assets Assets	1491013000
CY2022Q4	us-gaap	Assets Assets	1545444000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	42114000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	43274000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	196486000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	204678000
CY2023Q4	rare	Contract Liabilities Current ContractLiabilitiesCurrent	0
CY2022Q4	rare	Contract Liabilities Current ContractLiabilitiesCurrent	1479000
CY2023Q4	rare	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	12595000
CY2022Q4	rare	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	11779000
CY2023Q4	rare	Liabilities For Sales Of Future Royalties Current LiabilitiesForSalesOfFutureRoyaltiesCurrent	29242000
CY2022Q4	rare	Liabilities For Sales Of Future Royalties Current LiabilitiesForSalesOfFutureRoyaltiesCurrent	0
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	280437000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	261210000
CY2023Q4	rare	Operating And Finance Lease Liability Noncurrent OperatingAndFinanceLeaseLiabilityNoncurrent	30574000
CY2022Q4	rare	Operating And Finance Lease Liability Noncurrent OperatingAndFinanceLeaseLiabilityNoncurrent	19814000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	30058000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	31667000
CY2023Q4	rare	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	862325000
CY2022Q4	rare	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	875439000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	12205000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4820000
CY2023Q4	us-gaap	Liabilities Liabilities	1215599000
CY2022Q4	us-gaap	Liabilities Liabilities	1192950000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	82315590
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70197297
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	82000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	70000
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	9559
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	432000
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0
CY2023Q4	us-gaap	Treasury Stock Deferred Employee Stock Ownership Plan TreasuryStockDeferredEmployeeStockOwnershipPlan	432000
CY2022Q4	us-gaap	Treasury Stock Deferred Employee Stock Ownership Plan TreasuryStockDeferredEmployeeStockOwnershipPlan	0
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3662346000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3140019000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	647000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6573000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3387661000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2781022000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	275414000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	352494000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1491013000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1545444000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	434249000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	363329000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	351406000
CY2023	rare	Cost Of Sales CostOfSales	45209000
CY2022	rare	Cost Of Sales CostOfSales	28320000
CY2021	rare	Cost Of Sales CostOfSales	16008000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	648449000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	705789000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	497153000
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	309799000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	278139000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	219982000
CY2023	rare	Cost Of Sales And Operating Expenses CostOfSalesAndOperatingExpenses	1003457000
CY2022	rare	Cost Of Sales And Operating Expenses CostOfSalesAndOperatingExpenses	1012248000
CY2021	rare	Cost Of Sales And Operating Expenses CostOfSalesAndOperatingExpenses	733143000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-569208000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-648919000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-381737000
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	26688000
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	11074000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	1928000
CY2023	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	397000
CY2022	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-19299000
CY2021	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-42063000
CY2023	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	66004000
CY2022	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	43015000
CY2021	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	29422000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-337000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1566000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1687000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-608464000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-701725000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-452981000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1825000
CY2023	rare	Stock Issued During Period Value At Market Offering StockIssuedDuringPeriodValueAtMarketOffering	53299000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	134169000
CY2023	rare	Issuance Of Common Stock Upon Exercise Of Warrants And Under Equity Plan Awards Net Of Tax IssuanceOfCommonStockUponExerciseOfWarrantsAndUnderEquityPlanAwardsNetOfTax	8415000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	7220000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-606639000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	275414000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-606639000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-707421000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5696000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1044000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-606639000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-707421000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-454025000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.25
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.25
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-10.12
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-10.12
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.7
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.7
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73543862
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73543862
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69914225
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69914225
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	67795540
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	67795540
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-606639000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-707421000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-454025000
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	239000
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-724000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-550000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	6981000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4445000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1543000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	7220000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-5169000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2093000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-599419000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-712590000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-456118000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1154375000
CY2021	rare	Stock Issued During Period Value At Market Offering StockIssuedDuringPeriodValueAtMarketOffering	78943000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	105260000
CY2021	rare	Issuance Of Common Stock Under Equity Plan Awards Net Of Tax IssuanceOfCommonStockUnderEquityPlanAwardsNetOfTax	40101000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2093000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-454025000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	922561000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	131710000
CY2022	rare	Issuance Of Common Stock Under Equity Plan Awards Net Of Tax IssuanceOfCommonStockUnderEquityPlanAwardsNetOfTax	10813000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-5169000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-707421000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	352494000
CY2023	rare	Pre Funded Warrants And Stock Issued During Period Value At Underwritten Public Offering PreFundedWarrantsAndStockIssuedDuringPeriodValueAtUnderwrittenPublicOffering	326456000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-454025000
CY2023	rare	Allocated Share Based Compensation Expense Net Of Capitalized Inventory Cost AllocatedShareBasedCompensationExpenseNetOfCapitalizedInventoryCost	135227000
CY2022	rare	Allocated Share Based Compensation Expense Net Of Capitalized Inventory Cost AllocatedShareBasedCompensationExpenseNetOfCapitalizedInventoryCost	130377000
CY2021	rare	Allocated Share Based Compensation Expense Net Of Capitalized Inventory Cost AllocatedShareBasedCompensationExpenseNetOfCapitalizedInventoryCost	104952000
CY2023	rare	Research And Development In Process1 ResearchAndDevelopmentInProcess1	0
CY2022	rare	Research And Development In Process1 ResearchAndDevelopmentInProcess1	75033000
CY2021	rare	Research And Development In Process1 ResearchAndDevelopmentInProcess1	0
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	12842000
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-2699000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-6606000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	26006000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	18220000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13239000
CY2023	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	397000
CY2022	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-19299000
CY2021	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-42063000
CY2023	rare	Non Cash Collaboration Royalty Revenue NonCashCollaborationRoyaltyRevenue	69364000
CY2022	rare	Non Cash Collaboration Royalty Revenue NonCashCollaborationRoyaltyRevenue	21692000
CY2021	rare	Non Cash Collaboration Royalty Revenue NonCashCollaborationRoyaltyRevenue	17951000
CY2023	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	66004000
CY2022	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	43015000
CY2021	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	29422000
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2300000
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	230000
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-235000
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	22778000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	12068000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5432000
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6930000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9701000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3117000
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-15325000
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-3798000
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	29508000
CY2023	rare	Increase Decrease In Accounts Payable Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherOperatingLiabilities	2380000
CY2022	rare	Increase Decrease In Accounts Payable Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherOperatingLiabilities	87442000
CY2021	rare	Increase Decrease In Accounts Payable Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherOperatingLiabilities	32313000
CY2023	rare	Increase Decrease In Contract Liabilities IncreaseDecreaseInContractLiabilities	-1479000
CY2022	rare	Increase Decrease In Contract Liabilities IncreaseDecreaseInContractLiabilities	-7597000
CY2021	rare	Increase Decrease In Contract Liabilities IncreaseDecreaseInContractLiabilities	-57492000
CY2023	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-1619000
CY2022	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-1639000
CY2021	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	0
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-474806000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-380465000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-338695000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	44267000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	116123000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	73093000
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	75025000
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	526382000
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	614735000
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1012187000
CY2023	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	50672000
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	84275000
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	92896000
CY2023	rare	Proceeds From Sale Of Equity Investment ProceedsFromSaleOfEquityInvestment	0
CY2022	rare	Proceeds From Sale Of Equity Investment ProceedsFromSaleOfEquityInvestment	10094000
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1577000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	17963000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	18993000
CY2023	rare	Non Cash Interest Expense On Liability Related To The Sale Of Future Royalties Capitalized Into Ending Property Plant And Equipment NonCashInterestExpenseOnLiabilityRelatedToTheSaleOfFutureRoyaltiesCapitalizedIntoEndingPropertyPlantAndEquipment	9431000
CY2022	rare	Non Cash Interest Expense On Liability Related To The Sale Of Future Royalties Capitalized Into Ending Property Plant And Equipment NonCashInterestExpenseOnLiabilityRelatedToTheSaleOfFutureRoyaltiesCapitalizedIntoEndingPropertyPlantAndEquipment	11380000
CY2021	rare	Proceeds From Sale Of Equity Investment ProceedsFromSaleOfEquityInvestment	79843000
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	695525000
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	450706000
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	718111000
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2500000
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	30000000
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0
CY2023	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	5048000
CY2022	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	844000
CY2021	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	942000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	168000000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-291652000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-195372000
CY2023	rare	Proceeds From Royalties Received Financing Activities ProceedsFromRoyaltiesReceivedFinancingActivities	0
CY2022	rare	Proceeds From Royalties Received Financing Activities ProceedsFromRoyaltiesReceivedFinancingActivities	490950000
CY2021	rare	Proceeds From Royalties Received Financing Activities ProceedsFromRoyaltiesReceivedFinancingActivities	0
CY2023	rare	Proceeds From The Issuance Of Common Stock And Pre Funded Warrants In Connection With Underwritten Public Offerings Net Of Issuance Costs ProceedsFromTheIssuanceOfCommonStockAndPreFundedWarrantsInConnectionWithUnderwrittenPublicOfferingsNetOfIssuanceCosts	326456000
CY2022	rare	Proceeds From The Issuance Of Common Stock And Pre Funded Warrants In Connection With Underwritten Public Offerings Net Of Issuance Costs ProceedsFromTheIssuanceOfCommonStockAndPreFundedWarrantsInConnectionWithUnderwrittenPublicOfferingsNetOfIssuanceCosts	0
CY2021	rare	Proceeds From The Issuance Of Common Stock And Pre Funded Warrants In Connection With Underwritten Public Offerings Net Of Issuance Costs ProceedsFromTheIssuanceOfCommonStockAndPreFundedWarrantsInConnectionWithUnderwrittenPublicOfferingsNetOfIssuanceCosts	0
CY2023	rare	Proceeds From The Issuance Of Common Stock In Connection With At The Market Offering Net Of Issuances Costs ProceedsFromTheIssuanceOfCommonStockInConnectionWithAtTheMarketOfferingNetOfIssuancesCosts	53299000
CY2022	rare	Proceeds From The Issuance Of Common Stock In Connection With At The Market Offering Net Of Issuances Costs ProceedsFromTheIssuanceOfCommonStockInConnectionWithAtTheMarketOfferingNetOfIssuancesCosts	0
CY2021	rare	Proceeds From The Issuance Of Common Stock In Connection With At The Market Offering Net Of Issuances Costs ProceedsFromTheIssuanceOfCommonStockInConnectionWithAtTheMarketOfferingNetOfIssuancesCosts	78943000
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	8415000
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	10813000
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	40101000
CY2023	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-28000
CY2022	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-555000
CY2021	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-492000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	388142000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	501208000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	118552000
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	462000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1075000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1194000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	81798000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-171984000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-416709000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	137601000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	309585000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	726294000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	219399000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	137601000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	309585000
CY2023	rare	Operating And Finance Lease Liability From Obtaining Right Of Use Assets And Property Plant And Equipment OperatingAndFinanceLeaseLiabilityFromObtainingRightOfUseAssetsAndPropertyPlantAndEquipment	22162000
CY2022	rare	Operating And Finance Lease Liability From Obtaining Right Of Use Assets And Property Plant And Equipment OperatingAndFinanceLeaseLiabilityFromObtainingRightOfUseAssetsAndPropertyPlantAndEquipment	1168000
CY2021	rare	Operating And Finance Lease Liability From Obtaining Right Of Use Assets And Property Plant And Equipment OperatingAndFinanceLeaseLiabilityFromObtainingRightOfUseAssetsAndPropertyPlantAndEquipment	3142000
CY2021	rare	Non Cash Interest Expense On Liability Related To The Sale Of Future Royalties Capitalized Into Ending Property Plant And Equipment NonCashInterestExpenseOnLiabilityRelatedToTheSaleOfFutureRoyaltiesCapitalizedIntoEndingPropertyPlantAndEquipment	4650000
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of the Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, income taxes, stock-based compensation, revenue recognition, and the liabilities for sales of future royalties. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p>
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	213584000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	132944000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	307584000
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	2008000
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	862000
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3807000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3795000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2001000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	219399000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	137601000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	309585000
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2023Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	749239000
CY2022Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	884017000
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	734562000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1693000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	440000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	735815000
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	882363000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	407000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	6135000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	876635000
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	18859000
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	17486000
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	15110000
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	9280000
CY2023Q4	us-gaap	Inventory Net InventoryNet	33969000
CY2022Q4	us-gaap	Inventory Net InventoryNet	26766000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	373967000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	323107000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	83401000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	63381000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	290566000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	259726000
CY2023	rare	Depreciation Excluding Intangible Amortization DepreciationExcludingIntangibleAmortization	22200000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	363329000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	351406000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	434249000
CY2022	rare	Depreciation Excluding Intangible Amortization DepreciationExcludingIntangibleAmortization	15000000
CY2021	rare	Depreciation Excluding Intangible Amortization DepreciationExcludingIntangibleAmortization	12900000
CY2023Q4	rare	Research Clinical Study And Manufacturing Expenses ResearchClinicalStudyAndManufacturingExpenses	65326000
CY2022Q4	rare	Research Clinical Study And Manufacturing Expenses ResearchClinicalStudyAndManufacturingExpenses	73558000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	82936000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	78938000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	48224000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	52182000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	196486000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	204678000
CY2022Q1	rare	Upfront Payment UpfrontPayment	30000000
CY2023	rare	Regulatorymilestonepaymentsachieved Regulatorymilestonepaymentsachieved	10000000
CY2023	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P10Y
CY2023Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	173775000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7504000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	166271000
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	163775000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3670000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	160105000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	4903000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	4903000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	4903000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	4462000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	4022000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	14078000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	37271000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	434249000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	363329000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	351406000
CY2022Q4	rare	Contract With Customer Assets Liability Current ContractWithCustomerAssetsLiabilityCurrent	1479000
CY2021Q4	rare	Contract With Customer Assets Liability Current ContractWithCustomerAssetsLiabilityCurrent	9076000
CY2023	rare	Contract With Customer Liability Additions During Period ContractWithCustomerLiabilityAdditionsDuringPeriod	0
CY2022	rare	Contract With Customer Liability Additions During Period ContractWithCustomerLiabilityAdditionsDuringPeriod	89000
CY2023	rare	Contract With Customer Liability Deductions During Period ContractWithCustomerLiabilityDeductionsDuringPeriod	1479000
CY2022	rare	Contract With Customer Liability Deductions During Period ContractWithCustomerLiabilityDeductionsDuringPeriod	7686000
CY2023Q4	rare	Contract With Customer Assets Liability Current ContractWithCustomerAssetsLiabilityCurrent	0
CY2022Q4	rare	Contract With Customer Assets Liability Current ContractWithCustomerAssetsLiabilityCurrent	1479000
CY2023	rare	Lessee Operating Lease Expiry Year LesseeOperatingLeaseExpiryYear	2029
CY2023	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2023	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	multiple renewal periods
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	12883000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	11775000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	11209000
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	5272000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	4785000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	4142000
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	203000
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	343000
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	310000
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	0
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	37000
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	58000
CY2023	us-gaap	Lease Cost LeaseCost	18358000
CY2022	us-gaap	Lease Cost LeaseCost	16940000
CY2021	us-gaap	Lease Cost LeaseCost	15719000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	13400000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	13100000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	11800000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23900000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26000000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	16234000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	11932000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	8430000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5867000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	5887000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	6009000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	54359000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	11190000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	43169000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12595000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30574000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y6M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.096
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.067
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.051
CY2021Q4	rare	Liability For Sale Of Future Royalties LiabilityForSaleOfFutureRoyalties	351786000
CY2022	rare	Proceeds From Royalties Received Financing Activities ProceedsFromRoyaltiesReceivedFinancingActivities	490950000
CY2022	rare	Royalty Revenue RoyaltyRevenue	21692000
CY2022	rare	Non Cash Interest Expense On Liability For Sale Of Future Royalties And Capitalized To Property Plant And Equipment NonCashInterestExpenseOnLiabilityForSaleOfFutureRoyaltiesAndCapitalizedToPropertyPlantAndEquipment	54395000
CY2022Q4	rare	Liability For Sale Of Future Royalties LiabilityForSaleOfFutureRoyalties	875439000
CY2023	rare	Royalty Revenue RoyaltyRevenue	59307000
CY2023	rare	Non Cash Interest Expense On Liability For Sale Of Future Royalties And Capitalized To Property Plant And Equipment NonCashInterestExpenseOnLiabilityForSaleOfFutureRoyaltiesAndCapitalizedToPropertyPlantAndEquipment	75435000
CY2023Q4	rare	Liability For Sale Of Future Royalties LiabilityForSaleOfFutureRoyalties	891567000
CY2023	rare	Stock Issued During Period Shares At Market Offering StockIssuedDuringPeriodSharesAtMarketOffering	1175584
CY2023	rare	Proceeds From Issuance Of Common Stock At Market Offering ProceedsFromIssuanceOfCommonStockAtMarketOffering	53300000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7773367
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	72.56
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M6D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	8476000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	2123256
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	45.05
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	209793
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	13.07
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	899118
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	71.56
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8787712
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	67.43
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M20D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7558000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5415110
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	73.28
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y11M15D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	1214000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	8461973
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	67.96
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y3M14D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	6794000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4900000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2600000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	38800000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2700000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6200000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	36600000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	25.53
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	34.77
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	70.84
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	59700000
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	58700000
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	48100000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	135213000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	130368000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	104979000
CY2023	rare	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount Including Amount Expensed To Cost Of Goods Sold EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmountIncludingAmountExpensedToCostOfGoodsSold	1900000
CY2022	rare	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount Including Amount Expensed To Cost Of Goods Sold EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmountIncludingAmountExpensedToCostOfGoodsSold	2200000
CY2021	rare	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount Including Amount Expensed To Cost Of Goods Sold EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmountIncludingAmountExpensedToCostOfGoodsSold	1700000
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	219800000
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y2M12D
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-60000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	7336000
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	9700000
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	9000000
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	5500000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-608166000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-703411000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-455314000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-298000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	1686000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	2333000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-608464000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-701725000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-452981000
CY2023	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-3187000
CY2022	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	6062000
CY2021	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-14000
CY2023	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	3127000
CY2022	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	1274000
CY2021	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	1058000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1044000
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1608000
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1640000
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	157000
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1765000
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1640000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1825000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5696000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1044000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.008
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.004
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.073
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.059
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.072
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.007
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.001
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.005
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.003
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.006
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.008
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.018
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.012
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.013
CY2023	rare	Effective Income Tax Rate Reconciliation Change In Uncertain Tax Positions EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions	-0.014
CY2022	rare	Effective Income Tax Rate Reconciliation Change In Uncertain Tax Positions EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions	-0.012
CY2021	rare	Effective Income Tax Rate Reconciliation Change In Uncertain Tax Positions EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions	-0.014
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.241
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.240
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.279
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.005
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.002
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.001
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.003
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.008
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.002
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	266253000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	231835000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	305198000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	260546000
CY2023Q4	rare	Deferred Tax Assets Stock Option DeferredTaxAssetsStockOption	44795000
CY2022Q4	rare	Deferred Tax Assets Stock Option DeferredTaxAssetsStockOption	39784000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	27694000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	27029000
CY2023Q4	rare	Deferred Tax Asset Fixed Assets And Intangibles DeferredTaxAssetFixedAssetsAndIntangibles	33853000
CY2022Q4	rare	Deferred Tax Asset Fixed Assets And Intangibles DeferredTaxAssetFixedAssetsAndIntangibles	39233000
CY2023Q4	rare	Deferred Tax Assets Liability Related To Sale Of Future Royalties DeferredTaxAssetsLiabilityRelatedToSaleOfFutureRoyalties	205400000
CY2022Q4	rare	Deferred Tax Assets Liability Related To Sale Of Future Royalties DeferredTaxAssetsLiabilityRelatedToSaleOfFutureRoyalties	214900000
CY2023Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	8423000
CY2022Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	8971000
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	149898000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	75335000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	281000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3028000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1041795000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	900661000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1035836000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	894518000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	5959000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	6143000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	36017000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	37810000
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	30058000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	31667000
CY2011Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	200000
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	200000
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	141300000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	193800000
CY2023	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-1600000
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1600000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	66794000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	55360000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	46662000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	12562000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	11316000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	8542000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	642000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	377000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	356000
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	259000
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	200000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	79998000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	66794000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	55360000
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	1300000
CY2023Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	200000
CY2022Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2021Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2023Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	10800000
CY2022Q3	rare	Related Party Payment Of Contribution RelatedPartyPaymentOfContribution	1000000
CY2022Q3	rare	Related Party Transaction Contribution Period RelatedPartyTransactionContributionPeriod	P4Y
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-606639000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-707421000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-454025000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73543862
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73543862
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69914225
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69914225
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	67795540
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	67795540
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.25
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.25
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-10.12
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-10.12
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.7
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.7
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14160736
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11298516
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8217574
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-606000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-845000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1253000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-5728000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	647000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6573000

Files In Submission

Name	View Source	Status
0000950170-24-017879-index-headers.html	Edgar Link	pending
0000950170-24-017879-index.html	Edgar Link	pending
0000950170-24-017879.txt	Edgar Link	pending
0000950170-24-017879-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img215954057_0.jpg	Edgar Link	pending
img215954057_1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
rare-20231231.htm	Edgar Link	pending
rare-20231231.xsd	Edgar Link	pending
rare-ex10_18.htm	Edgar Link	pending
rare-ex10_30.htm	Edgar Link	pending
rare-ex10_31.htm	Edgar Link	pending
rare-ex10_32.htm	Edgar Link	pending
rare-ex10_33.htm	Edgar Link	pending
rare-ex10_34.htm	Edgar Link	pending
rare-ex10_35.htm	Edgar Link	pending
rare-ex10_36.htm	Edgar Link	pending
rare-ex21_1.htm	Edgar Link	pending
rare-ex23_1.htm	Edgar Link	pending
rare-ex31_1.htm	Edgar Link	pending
rare-ex31_2.htm	Edgar Link	pending
rare-ex32_1.htm	Edgar Link	pending
rare-ex97_1.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
rare-20231231_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RARE
Ultragenyx Pharmaceutical Inc. Stock $rare

2024 Q1 Form 10-K Financial Statement

#000095017024017879 Filed on February 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RARE Ultragenyx Pharmaceutical Inc. Stock $rare

2024 Q1 Form 10-K Financial Statement

#000095017024017879 Filed on February 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RARE
Ultragenyx Pharmaceutical Inc. Stock $rare